JW THERAP-B (02126) announced its interim results for the six months ended June 30, 2025, reporting revenue of RMB 106 million, representing a year-on-year increase of 22.5%. Gross profit reached RMB 65.12 million, up 48.86% compared to the same period last year, while research and development expenses totaled RMB 92.04 million.

According to the announcement, for the six months ended June 30, 2025, and up to the date of this announcement, as an independent innovative biotechnology company focused on developing, manufacturing and commercializing cellular immunotherapy products, the Group achieved further significant business progress and important milestones with comprehensive operational efficiency improvements. These include maintaining stable gross profit margins, expanding marketing activities while effectively controlling sales expenses, organizational streamlining, and reduced net cash outflows.

The Group's leading product Beinuoda® continued to make progress in commercialization. Additionally, the Group has completed patient enrollment for the clinical trial of Beinuoda® as second-line treatment for patients with relapsed or refractory (r/r) large B-cell lymphoma (LBCL) who are ineligible for transplantation. Based on this indication, the National Medical Products Administration granted Beinuoda® "Breakthrough Therapy Designation" in January 2025, and the Group submitted a supplemental New Drug Application (sNDA) in May 2025.

Furthermore, the Group has developed its proprietary platform process and successfully produced lentiviral vectors for manufacturing Beinuoda®, thereby further reducing product costs. Analysis and clinical studies have demonstrated results comparable to current lentiviral vectors. The Group has completed patient enrollment for the Investigational New Drug (IND) application for these vectors.

Moreover, the Group has made significant progress in developing innovative products with global commercialization potential.